Meeting
2013 Gastrointestinal Cancers Symposium
Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).
Authors
Anthony Chan
Sir YK Pao Center for Cancer, State Key Laboratory
Anthony Chan , Stephen Chan , Wing Ho , Wilson Lau , Frankie Mo , Edwin Hui , Charles Chan , Annette Poon , Rasalkar Dattatray , S. C. Wong , Ka Fai To , Ann King , Anil Ahuja , Brigette Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01243047
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr425)
DOI
10.1200/jco.2013.31.4_suppl.425
Abstract #
425
Poster Bd #
B37
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).
First Author: Evaristo Maiello
Poster
2013 Gastrointestinal Cancers Symposium
Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study).
First Author: Ho Min Kim
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2020 Gastrointestinal Cancers Symposium
A multicenter phase II trial of tumor treating fields plus chemotherapy for first-line treatment of gastric adenocarcinoma.
First Author: Jin Li